ONPATTRO - (10MG/5ML ; Solution)

Generic Name	PATISIRAN SODIUM	**Innovator**	Alnylam Pharms INC
Dosage	10MG/5ML ; Solution	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	ONPATTRO contains a transthyretin-directed small interfering RNA and is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.